行情

VVUS

VVUS

VIVUS
NASDAQ

实时行情|Nasdaq Last Sale

2.860
+0.060
+2.14%
已收盘, 16:00 11/15 EST
开盘
2.900
昨收
2.800
最高
2.900
最低
2.822
成交量
4.27万
成交额
--
52周最高
5.78
52周最低
2.150
市值
3,043.82万
市盈率(TTM)
-1.0330
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VVUS 新闻

  • Edited Transcript of VVUS earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.21小时前
  • VVUS: Never In a Straight Line
  • Zacks Small Cap Research.4天前
  • VIVUS, Inc. (VVUS) CEO John Amos on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/06 03:30
  • Vivus EPS misses by $0.30, misses on revenue
  • seekingalpha.11/06 02:09

更多

所属板块

制药
+1.26%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

VVUS 简况

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
展开

Webull提供VIVUS, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。